ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Overview of the postpartum period: Normal physiology and routine maternal care

Overview of the postpartum period: Normal physiology and routine maternal care
Literature review current through: Jan 2024.
This topic last updated: May 31, 2023.

INTRODUCTION — The postpartum period, also known as the puerperium and the "fourth trimester," refers to the weeks after birth when the physiologic changes related to pregnancy return to the nonpregnant state. In addition to physiologic changes and medical issues that may arise during this period, obstetric health care providers should be aware of the mental health needs of the postpartum mother and be sensitive to different cultural practices related to childbirth, which may involve eating particular foods and restricting certain activities [1]. Lastly, obstetric providers can help patients to transition to primary care providers. This is particularly important for patients with placenta-mediated disorders such as fetal growth restriction, preeclampsia, and abruption and those with gestational diabetes who need counseling and ongoing follow-up regarding their increased risks for developing cardiovascular disease and diabetes mellitus.

This topic will provide an overview of normal physiologic changes and routine maternal care during the postpartum period. An overview of postpartum disorders and complications and their management is available separately. (See "Overview of the postpartum period: Disorders and complications".)

DEFINITION OF THE POSTPARTUM PERIOD — There is consensus that the postpartum period begins upon birth of the newborn. The end is less well defined, but is often considered the six to eight weeks after birth because the effects of pregnancy on many systems have largely returned to the prepregnancy state by this time. However, all organ systems do not return to baseline within this period, and the return to baseline is not necessarily linear over time. For this reason, the American College of Obstetricians and Gynecologists considers postpartum care to extend up to 12 weeks after birth [2] and calls these 12 weeks the "fourth trimester." Some investigators have considered individuals to be postpartum for as long as 12 months after birth.

POSTPARTUM FINDINGS AND CHANGES

Shivering — Postpartum shivering or chills are observed in 25 to 50 percent of postpartum individuals [3,4]. Shivering usually starts 1 to 30 minutes after giving birth and lasts for 2 to 60 minutes. The cause is unknown; it may be a response to a fall in body temperature following labor, fetal-maternal bleeding, micro-amniotic emboli, placental separation, anesthesia, bacteremia, or administration of certain drugs (eg, misoprostol).

Treatment is supportive with warm blankets and/or warm air. Anesthesia-related shivering can be treated pharmacologically. (See "Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Shivering'.)

Uterine involution

Signs and symptoms — Immediately after delivery of the placenta, the uterus begins to return to its nonpregnant state, a process termed uterine involution. Contraction of the interlacing myometrial muscle bundles constricts the intramyometrial vessels and impedes blood flow, which is the major mechanism preventing hemorrhage at the placental site. Myometrial retraction (brachystasis) is a unique characteristic of the uterine muscle that enables it to maintain its shortened length following successive contractions. Inadequate myometrial contraction will result in atony (ie, a soft, boggy uterus), which is the most common cause of early postpartum hemorrhage. In addition to myometrial contraction, large vessels at the placental site thrombose, which is a secondary hemostatic mechanism for preventing blood loss.

Immediately after birth, the fundus is normally firm, nontender, globular, and located midway between the symphysis pubis and umbilicus. In the next 12 hours, it rises to just above or below the umbilicus, then recedes by approximately 1 cm/day to again lie midway between the symphysis pubis and umbilicus by the end of the first postpartum week. It is not palpable abdominally by two weeks postpartum and attains its normal nonpregnant size by six to eight weeks postpartum. This process is modestly affected by predelivery uterine overdistention, multiparity, and cesarean birth (the uterus is slightly larger in these cases), and by breastfeeding (the uterus is slightly smaller at three months postpartum in breastfeeding individuals [5]). The weight of the uterus decreases from approximately 1000 g immediately postpartum to 60 g six to eight weeks later.

Although assessment of uterine size is routinely performed in the early postnatal period, there is no evidence that uterine size is predictive of complications [6,7].

Findings on ultrasound — The normal sonographic appearance of the postpartum uterus was illustrated by a prospective, longitudinal study that performed ultrasound examinations on postpartum days 1, 3, 7, 14, 28, and 56 in 42 individuals with uncomplicated term vaginal births [8]. The uterus was most often empty in the early puerperium (days 1 and 3), fluid and debris were seen in the entire cavity in the middle part of the puerperium (day 14), while the late puerperium (days 28 and 56) was characterized by an empty cavity that appeared as a thin white line. Endometrial gas was occasionally seen. Gas in the uterine cavity may be seen after cesarean birth or after manual evacuation of the placenta [9]. Others have reported that intrauterine echogenic material is commonly seen in the first 48 hours after vaginal birth and is not associated with the amount or duration of bleeding [10-12].

These observations suggest that the presence of echogenic material can be a normal finding and need not change clinical management in patients who do not have heavy bleeding or signs of uterine infection. However, in patients with fever and/or bleeding, an echogenic mass may represent retained products of conception (image 1) [13]. (See "Secondary (late) postpartum hemorrhage", section on 'Retained products of conception (RPOC)'.)

Lochia — The basal portion of the decidua remains after the placenta separates. This decidua divides into two layers: The superficial layer is shed and the deep layer regenerates new endometrium, which covers the entire endometrial cavity by the 16th postpartum day [14]. During the first few days following birth, normal shedding of blood and decidua is red/red-brown (lochia rubra). The vaginal discharge then becomes increasingly watery and pinkish brown (lochia serosa), which lasts for two to three weeks. Ultimately, the discharge turns yellowish white (lochia alba). Microscopically, lochia consists of serous exudate, erythrocytes, leukocytes, decidua, epithelial cells, and bacteria.

The total volume of postpartum lochial secretion is 200 to 500 mL, which is discharged over a mean duration of one month [15]. Up to 15 percent of individuals continue to pass lochia when seen for a routine postpartum visit six to eight weeks after giving birth [16]. The duration of lochia does not appear to be related to lactation or to the use of either estrogen-containing or progesterone-only contraceptives, but individuals with bleeding diatheses may be prone to a longer duration of passing lochia [17].

Cervix — The cervix is soft and floppy after birth. Small lacerations can be found at the margins of the external os. The cervix remains 2 to 3 cm dilated for the first few postpartum days and is less than 1 cm dilated at one week. The external os never resumes its pregravid shape; the small, smooth, regular circular opening of the nulligravida becomes a large, transverse, stellate slit after childbirth (figure 1). Histologically, the cervix does not return to baseline for up to three to four months after birth [18].

Vagina, hymen, pelvic muscles — The vagina is capacious and smooth immediately after birth. It slowly contracts, but not to its nulligravid size; rugae are restored in the third postpartum week as edema and vascularity subside.

The hymen is replaced by multiple tags of tissue called the carunculae hymenales (myrtiformes).

Fascial stretching and trauma during childbirth result in pelvic muscle relaxation, which may not return to the pregravid state. (See "Effect of pregnancy and childbirth on urinary incontinence and pelvic organ prolapse".)

Abdominal wall — The abdominal wall is lax postpartum but regains most, if not all, of its normal muscular tone over several weeks; however, separation (diastasis) of the rectus abdominis muscles may persist. Long-term sequelae may include abdominal discomfort and cosmetic issues, which may be managed conservatively or surgically. (See "Rectus abdominis diastasis".)

hCG, hot flashes, resumption of ovulation

Human chorionic gonadotropin (hCG) levels – The normal fall and disappearance of hCG postpartum has an initial rapid phase and then a more gradual decline [19-21]. In one study of 10 healthy mothers, the median time to elimination was 14 days following vaginal birth (range 8 to 24 days) [19]. The most serious concern in patients with rising hCG levels postpartum is gestational trophoblastic disease. (See "Hydatidiform mole: Epidemiology, clinical features, and diagnosis", section on 'hCG'.)

Hot flashes – Some individuals report hot flashes in the postpartum period, with resolution over time [22]. The cause is unknown but may be due to thermoregulatory dysfunction, initiated at the level of the hypothalamus by estrogen withdrawal after delivery of the placenta. In addition, the initial hyperprolactinemic state associated with breastfeeding depresses estrogen production.

Resumption of ovulation – Gonadotropins and sex steroids are at low levels for the first two to three weeks postpartum. In studies using urinary pregnanediol levels to measure ovulation in nonlactating postpartum individuals, the mean return of menstruation following birth ranged from 45 to 64 days postpartum, and the mean time to ovulation ranged from 45 to 94 days but occurred as early as 25 days [23]. Seventy percent of individuals will menstruate by the 12th postpartum week, and 20 to 71 percent of first menstruations are preceded by ovulation; thus, the cycle is potentially fertile.

The degree to which breastfeeding suppresses gonadotropin-releasing hormone (GnRH) secretion is modulated by the intensity of the breastfeeding and maternal nutritional status and body mass [24-26]. Lactation represents a metabolic energy burden. When nutrition is adequate and basal body mass and composition are normal, intensive lactation is less likely to result in prolonged suppression of GnRH [27,28]. When nutrition is inadequate to meet the energy demands of both daily living and lactation, GnRH suppression is more likely to persist for an extended time period, resulting in prolonged oligo- or anovulation. During exclusive breastfeeding, approximately 40 percent of individuals will remain amenorrheic at six months postpartum [29,30]. Amenorrhea during breastfeeding may be related, in part, to higher prolactin levels compared with individuals who become ovulatory while breastfeeding, since prolactin inhibits pulsatile GnRH release from the hypothalamus [31]. In one study, some individuals who exclusively breastfed (at least six episodes of suckling/day totaling more than 80 minutes in 24 hours) had elevated basal prolactin levels and amenorrhea for one year or more after giving birth [32]. (See "Contraception: Postpartum counseling and methods", section on 'Other'.)

Breast engorgement — Breast engorgement results in breast fullness and firmness, which is accompanied by pain and tenderness. The affected area varies from primarily areolar involvement in some mothers, more peripheral involvement in others, and, in some mothers, both peripheral and areolar involvement. Primary engorgement is due to interstitial edema and onset of copious milk production. It typically occurs between 24 and 72 hours postpartum, with a normal range of one to seven days; peak symptomatology averages three to five days postpartum though cesarean birth may delay symptoms slightly. Secondary engorgement typically occurs later if the mother's milk supply exceeds the amount of milk removed by her newborn.

Breast engorgement is uncomfortable and may give rise to a mild temperature elevation for a short time; however, any fever should prompt an investigation to rule out an infectious source. (See "Overview of the postpartum period: Disorders and complications", section on 'Fever/infection/wound complications'.).

Management of breast engorgement and lactation suppression are discussed below. (See 'Management of breast engorgement and lactation suppression' below.)

Skin and hair

Striae, if present, fade from red to silvery but are permanent.

Abdominal skin may remain lax if extensive rupture of elastic fibers occurred during pregnancy.

Chloasma resolves, although the time course has not been studied.

The increase in the ratio of "growing" or anagen hair relative to the "resting" or telogen hair during pregnancy reverses in the puerperium. Telogen effluvium is the hair loss commonly noted one to five months after giving birth. It is usually self-limited with restoration of normal hair patterns by 6 to 15 months postpartum.

All of these changes and potential interventions, where available, are described in detail separately. (See "Maternal adaptations to pregnancy: Skin and related structures".)

Physiologic weight loss — The mean weight loss from expulsion of the fetus, placenta, and amniotic fluid is 13 pounds (6 kg). Contraction of the uterus and loss of lochial fluid and excess intra- and extracellular fluid leads to an additional loss of 5 to 15 pounds (2 to 7 kg) during the puerperium. Approximately one-half of gestational weight gain is lost in the first six weeks after birth, with a slower rate of loss through the first six months postpartum [33]. (See "Overview of the postpartum period: Disorders and complications", section on 'Postpartum weight retention'.)

Cardiovascular system — Physiologic changes in the cardiovascular system are particularly important in patients with underlying cardiac disease. Within the first 10 minutes following a term vaginal birth, the cardiac output and stroke volume increase by approximately 60 and 70 percent, respectively. At one hour postpartum, both the cardiac output and stroke volume remain increased (by approximately 50 and 70 percent, respectively) while the heart rate decreases by 15 percent; blood pressure remains unchanged. The increases in stroke volume and cardiac output most likely result from improved cardiac preload from auto transfusion of uteroplacental blood to the intravascular space. As the uterus decompresses following birth, a reduction in the mechanical compression of the vena cava allows for further increases in preload.

A study that evaluated cardiac output and stroke volume in 15 healthy nonlaboring patients at 38 weeks of gestation and again at 2, 6, 12, and 24 weeks postpartum demonstrated a gradual diminution in cardiac output from 7.42 L/min at 38 weeks of gestation to 4.96 L/min at 24 weeks postpartum [34]. As early as two weeks postpartum, there were substantial reductions in left ventricular size and contractility as compared with term pregnancies. (See "Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes", section on 'Postpartum changes'.)

The new-onset of hypertension postpartum has been reported in 0.3 to 7.5 percent of individuals after giving birth [35]. Causes include intrapartum/postpartum volume overload, medications (eg, ergot derivatives), pregnancy-associated hypertension (eg, preeclampsia), and underlying medical disorders. In patients with antepartum/intrapartum preeclampsia, blood pressure typically decreases within 48 hours of birth, but can increase again three to six days postpartum. Because hypertension may present or recur after hospital discharge and may be asymptomatic, a blood pressure check soon after discharge is advised in high-risk patients, especially those with preeclampsia that appeared to be resolving. ACOG suggests daily blood pressure evaluation for 72 hours postpartum and again around 7 to 10 days postpartum, or earlier in patients with symptoms [2,36]. Another approach is to ensure measurement at least once during postpartum days three to five [37]. Adjunctive home blood pressure monitoring, if possible, is useful for early recognition of hypertension [38]. (See "Treatment of hypertension in pregnant and postpartum patients", section on 'Monitoring after discharge'.)

Patients who were normotensive during pregnancy and while in the hospital after giving birth still need to be aware of the possibility of delayed postpartum preeclampsia and call their provider if they develop symptoms (eg, headache, epigastric pain, visual changes). (See "Preeclampsia: Clinical features and diagnosis", section on 'Onset or exacerbation of symptoms >2 days postpartum'.)

Hematologic system — Pregnancy-related hematologic changes return to baseline by 6 to 12 weeks after giving birth. Within this range, the rate and pattern of resolution of pregnancy-related changes of specific hematological parameters vary. Importantly, the prothrombotic state takes weeks to resolve, so postpartum individuals remain at increased risk for thromboembolic disease. (See "Maternal adaptations to pregnancy: Hematologic changes" and 'Prevention of venous thrombosis' below.)

Patients with a bleeding diathesis are at risk for postpartum hemorrhage. A qualitative study of females with inherited bleeding disorders found that they were desensitized to heavy vaginal blood loss and therefore many did not recognize excessive postpartum bleeding when it occurred [39].

ROUTINE MATERNAL CARE — Providing support and reassurance during the postpartum period helps to instill a sense of confidence in parents and can also help foster a healthy parent-child relationship. A systematic review of studies on maternal expectations in the postnatal period found that they wanted to achieve positive motherhood (maternal self-esteem, competence, and autonomy), successfully adapt to the changes in intimate and family relationships, and (re)gain health and well-being for their child and themselves [40].

Rooming in — Rooming in 24 hours a day is one component of the Baby-friendly Hospital Initiative launched by the World Health Organization and UNICEF. Keeping the newborn's crib by the side of the mother's bed rather than in a nursery is thought to improve successful breastfeeding, although a systematic review found little evidence to support or refute the practice of rooming in versus mother-newborn separation on the duration of breastfeeding [41].

In the United States, the term "Baby-Friendly" is reserved for use by facilities who have demonstrated through an on-site assessment that they have met the criteria outlined in the most current version of the Guidelines and Evaluation Criteria.

Maternal monitoring — In addition to routine vital signs:

The key components of identifying postpartum hemorrhage are fundal checks to assess uterine tone and perineal checks to assess for excessive vaginal bleeding. These assessments should be conducted by skilled nurses and are commonly performed hourly for the first 2 hours after birth and then continued every 4 hours during the initial 24 hours postpartum.

A normal postpartum fundus is firm and well-contracted, typically at or below the level of the maternal umbilicus. Excessive vaginal bleeding is a subjective assessment in the absence of hemodynamic instability. Fundal massage is a useful and expeditious intervention if the uterus is not firm. (See "Overview of postpartum hemorrhage", section on 'Criteria for diagnosis' and "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Manage atony'.)

The suprapubic area is palpated to identify an overdistended bladder; a distended bladder is palpable abdominally. (See "Overview of the postpartum period: Disorders and complications", section on 'Voiding difficulty and urinary retention'.)

The perineum is examined for signs of edema, purulent discharge, or dehiscence. (See "Overview of the postpartum period: Disorders and complications", section on 'Fever/infection/wound complications'.)

Laboratory testing

Hemoglobin/hematocrit – Evaluation of postpartum hemoglobin may be individualized based on specific patient characteristics. Routine postpartum hemoglobin testing is generally prudent, and is warranted in situations such as prepartum anemia or postpartum hemorrhage, and in the symptomatic patient. It may be omitted in patients who were not anemic upon admission, had an uncomplicated labor and vaginal birth, had estimated blood loss <500 mL at the time of birth (which eliminates most cesarean births), and are asymptomatic [42-45]. Although one study reported that 11 percent of patients with measured postpartum blood loss <500 mL had a postpartum fall in hemoglobin ≥2 g/dL after vaginal birth [46], this could have been due to multiple factors, including inaccurate measurement of blood loss, bleeding after the patient left the birthing room, peripartum fluid shifts, and hemoglobin assessment in different laboratories.

White blood cell count – Determination of the white blood cell count is not predictive of impending infection since leukocytosis as high as 15,000 cells/microL occurs frequently in postpartum patients [47,48]. Laboratory assessment of white blood cell count and differential can be reserved for patients in whom there is a clinical suspicion of infection.

Perineal care — There is a paucity of evidence-based information regarding care of the perineum after childbirth. A squirt bottle and sitz bath are commonly recommended for perineal care. Comfort measures include topical treatments (eg, cold or warm packs), topical anesthetics, and oral analgesics. Eating a high-fiber diet and drinking plenty of water, with stool softeners and laxatives as needed, are probably useful until perineal healing is nearly complete, especially in patients with a disrupted anal sphincter. (See "Postpartum perineal care and management of complications".)

Management of breast engorgement and lactation suppression

Management of breast engorgement — Breast engorgement spontaneously resolves over a few days, but supportive care (eg, warm compresses or a warm shower before feeding to enhance let-down and facilitate milk removal, cool compresses after or between feedings, reverse pressure softening, mild analgesics such as acetaminophen [paracetamol] or ibuprofen) is appropriate and reviewed separately. Vigorous breast massage should be avoided due to concern for tissue damage and increased risk for infection. (See "Common problems of breastfeeding and weaning", section on 'Engorgement'.)

In individuals who are not breastfeeding, the use of a tight brassiere and avoidance of breast stimulation suppresses lactation in 60 to 70 percent of individuals and is the recommended treatment; there are no high-quality studies comparing use of nondrug approaches with no treatment [49].

Lactation suppression — Medication for suppression of lactation is not recommended because the potential risks associated with available drugs generally outweigh the benefit for self-limited mild-to-moderate symptoms. In the past, bromocriptine was used to prevent/treat these symptoms, but was abandoned because of reports of rare but serious complications such as postpartum hypertension, seizures, and stroke.

A contemporary study including 73 patients experiencing second-trimester pregnancy loss or termination suggested that cabergoline (a dopamine receptor agonist) was effective for reducing breast symptoms compared with placebo through day 14 and not associated with an increased risk of side effects, but the number of patients was too small to accurately determine the overall frequency of side effects and any risk of uncommon serious morbidities [50]. In systematic reviews, the most common side effects were dizziness, headache, and nausea or vomiting [51,52]. The authors of one of these reviews suggested caution in patients with a personal or family history of psychotic illness as a subgroup potentially at higher risk of adverse events; however, the quality of evidence was poor to fair [51].

If cabergoline is used in a patient with fetal demise/stillbirth who desires lactation inhibition after a thorough discussion of the potential risks and side effects, a single 1 mg is administered orally, ideally within the first 24 hours after fetal expulsion. Hypertension is a contraindication to use.

Support for breastfeeding and breast care — Human milk is recognized as the optimal food for all infants because of its proven health benefits to both infants and their mothers. Breastfeeding support by the health care provider, peers, and/or lactation consultant is associated with higher breastfeeding rates after hospital discharge. Multiple issues related to breastfeeding are discussed in detail separately.

(See "Infant benefits of breastfeeding" and "Maternal and economic benefits of breastfeeding".)

(See "Breastfeeding: Parental education and support".)

(See "Initiation of breastfeeding".)

(See "Maternal nutrition during lactation".)

(See "Common problems of breastfeeding and weaning".)

(See "Breastfeeding the preterm infant".)

Problems such as mastitis lead many individuals to discontinue breastfeeding. The occurrence of mastitis can be minimized by frequent, complete emptying of the breast and by optimizing breastfeeding technique (eg, breast massage before latching, correct infant position and attachment, alternating the breast that feeds are started from). (See "Lactational mastitis".)

Prevention of venous thrombosis — Thromboembolic events are a leading cause of direct maternal mortality worldwide, especially in high income countries. Venous thromboembolism (VTE) is more common in pregnancy, more common postpartum than antepartum, and more common after cesarean than vaginal birth [53,54]. The risk is highest in the first few weeks postpartum and then gradually declines to baseline by 12 weeks postpartum [55]. Several factors increase the risk, including but not limited to previous VTE, inherited or acquired thrombophilia, certain medical comorbidities (eg, sickle cell disease), obesity, smoking, cesarean birth, and postpartum hemorrhage [56].

Prophylaxis is recommended for individuals at high risk of having a thromboembolic event, although specific criteria to identify these individuals vary among institutions and guidelines. Indications for postpartum thromboprophylaxis and drug regimens are reviewed separately:

(See "Cesarean birth: Preoperative planning and patient preparation", section on 'Thromboembolism prophylaxis'.)

(See "Venous thromboembolism in pregnancy: Prevention".)

(See "Inherited thrombophilias in pregnancy", section on 'Prevention of VTE'.)

(See "Antiphospholipid syndrome: Obstetric implications and management in pregnancy", section on 'Postpartum care'.)

Routine immunizations — Indications and procedures for vaccination of postpartum individuals are similar to those described for the general population. Both inactivated and live vaccines (except smallpox vaccine) may be administered to nursing mothers. Postpartum individuals, including those who are breastfeeding, should receive all recommended vaccines that could not be, or were not, administered during pregnancy ( (table 1), eg, measles/mumps/rubella, varicella, Tetanus toxoids diphtheria acellular pertussis [Tdap], human papillomavirus, influenza, COVID-19). Postpartum immunization is discussed in detail separately. (See "Immunizations during pregnancy", section on 'Postpartum immunization'.)

All household members in the newborn's home should also have up-to-date immunizations (figure 2) to create a protective "cocoon" around the infant and thus minimize newborn exposure to infection; Tdap, influenza, and COVID-19 vaccines are particularly important in this respect. (See "Standard immunizations for nonpregnant adults" and "Standard immunizations for children and adolescents: Overview", section on 'Infants and children'.)

Anti-D immune globulin — RhD-negative mothers of RhD-positive infants should be given anti-D immune globulin soon after birth and within 72 hours. We suggest routinely testing all RhD-negative mothers for excessive fetomaternal bleeding at the time of birth to ensure that they receive an adequate dose of anti-D immune globulin. (See "RhD alloimmunization: Prevention in pregnant and postpartum patients".)

Pelvic muscle exercises — Pelvic floor muscle exercises (PFME) performed during pregnancy help to decrease the short-term risk of urinary incontinence in individuals without prior incontinence, but a long-term benefit has not been established. PFME in the immediate postpartum period may be contraindicated in individuals who sustain injury to the levator ani muscle complex at childbirth because exercise may be harmful in the early phase of injury recovery. In individuals with obstetrical anal sphincter injuries, postpartum pelvic floor physical therapy after two weeks appears to improve pelvic floor symptoms by 12 weeks postpartum compared with standard care [57,58]. (See "Effect of pregnancy and childbirth on urinary incontinence and pelvic organ prolapse", section on 'Prophylactic pelvic floor muscle exercises'.)

Pain management — The pain trajectory after giving birth has not been studied extensively, but should be considered in planning pain management. In a prospective study, pain severity generally declined rapidly over the first 14 days after cesarean birth, and then more gradually [59]. Approximately 90 percent of patients did not have significant pain by two months after cesarean. In another study, the median time to pain resolution after vaginal birth was 7 to 14 days and for cesarean birth 12 to 27 days [60]. Cesarean birth was also associated with greater pain intensity. Both studies noted significant variability among participants.

Afterpains — Afterpains occur in 50 percent of individuals within 48 hours of vaginal or cesarean birth due to hypertonic uterine contractions [61]. The pain is intermittent and often more intense during nursing due to the release of oxytocin associated with suckling. It is more common in multiparous individuals, individuals in whom the uterus was overdistended before birth (eg, multiple gestation, polyhydramnios), and individuals with a history of dysmenorrhea. Afterpains usually spontaneously resolve by the end of the first postpartum week.

Mild analgesics (eg, acetaminophen [paracetamol], ibuprofen, diclofenac suppositories) are effective [62]. Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to be as effective as acetaminophen (paracetamol), and the two drugs can be used in combination if a single drug is inadequate. Opioids are unnecessary and should be avoided. Severe afterpains after vaginal birth are atypical and should prompt an evaluation for another source.

Vaginal birth — NSAIDs or acetaminophen are the preferred initial analgesics after a vaginal birth. Prescribing opioids following vaginal birth is associated with future persistent opioid misuse, even after adjustment of confounding factors [63]. After a vaginal birth, the risk that an opioid-naïve mother exposed to opioids will become a persistent opioid user was reported to be 0.59 percent [64] and 1.7 percent [65] in two studies. In individuals who have an epidural and require a forceps- or vacuum-assisted vaginal birth or extensive perineal repairs, the addition of a long-acting agent to the epidural may reduce postpartum opioid use [66,67]. (See "Neuraxial analgesia for labor and delivery (including instrumental delivery)".)

If NSAIDs or acetaminophen is ineffective, the next step would be the addition of a low dose of a low potency opioid (eg, codeine, hydrocodone, oxycodone, tramadol, morphine) for a short duration; however, newborn effects need to be considered in breastfeeding patients (see 'Breastfeeding issues' below). If ineffective, a higher potency opioid (eg, hydromorphone, fentanyl) may be added, but the need for such agents is unusual after an uncomplicated vaginal birth so the reason for severe pain should be investigated (eg, previously unsuspected vaginal hematoma).

Perineal pain — Comfort measures include oral analgesics (eg, acetaminophen [paracetamol], ibuprofen) and topical treatments (eg, cold or warm packs applied for 10 to 20 minutes) as first-line therapies; some patients benefit from topical anesthetics. Opioids should be avoided, although a minority of individuals may need a short course if they are experiencing moderate pain unrelieved by these measures and another source for the pain has been ruled out. (See "Postpartum perineal care and management of complications", section on 'Pain management'.)

Cesarean birth — Multimodal strategies for postoperative pain control after cesarean birth should be employed to promote rapid recovery, allow the patient to care for their newborn, and minimize the need for postoperative opioids (table 2) [68]. A step-wise approach should be employed using agents with different mechanisms of action. Patients who receive neuraxial anesthesia benefit from neuraxial morphine or hydromorphone. The use of local anesthetic blocks at the time of cesarean, such as transverse abdominis plane or quadratus lumborum blocks, can decrease immediate postoperative pain and decrease need for narcotics [69]. (See "Post-cesarean delivery analgesia".)

Multiple factors affect the patient's experience of post-cesarean pain and adequate relief of this pain is a metric of patient satisfaction. However, opioid use for acute pain, although effective, is associated with an increased risk of long-term opioid use: After a cesarean birth, the reported risk that an opioid-naïve patient exposed to opioids will become a persistent opioid user was reported to be 0.12 percent [70], 0.36 percent [71], 0.84 percent [64], and 2.2 percent [65] in four studies.

Providers should consider limiting initial prescription amounts and requesting that patients contact their provider for possible evaluation if additional opioids are needed [72]. A 2019 review noted that patients used approximately 10 tablets of the prescribed opioid after discharge from cesarean birth and that the quantity prescribed influenced the number of tablets taken. The rationale for limiting opioid prescriptions and a strategy for prescription of opioids for acute pain in opioid-naïve patients based on severity and expected duration of pain can be found separately. (See "Approach to the management of acute pain in adults".)

Safety of common analgesics in breastfeeding individuals — Most analgesics are safe for breastfeeding individuals, with the following caveats. Detailed information on specific drugs can be found in the UpToDate drug information database (each drug includes a section on breastfeeding implications) or in LactMed.

Preferred drugs:

Acetaminophen (paracetamol) – Acetaminophen (paracetamol) enters breast milk but is considered compatible with breastfeeding by the Academy of Breastfeeding Medicine (ABM) [73]. It is the preferred analgesic for breastfeeding individuals.

NSAIDsIbuprofen and diclofenac suppositories, which have a short half-life (<6 hours), have relative infant doses of less than 1 percent and are considered compatible with breastfeeding by ABM [73]. Naproxen should be avoided because alternative NSAIDs are available and it has a long half-life (>6 hours), thus a greater potential to accumulate in the infant's plasma. All NSAIDs should be avoided if the breast-fed infant has a ductal-dependent cardiac lesion [74].

Intravenous or oral ketorolac can be used with acetaminophen or ibuprofen to treat moderate pain in breastfeeding individuals [68]. The concentration in breast milk is likely to be minimal. The combination of ketorolac and acetaminophen or ibuprofen may achieve adequate analgesia so that opioids can be avoided.

Use of opioids for patients with severe pain – Adequate treatment of maternal pain is an important factor for improving breastfeeding outcome. Although opioid analgesia postpartum may affect newborn alertness and suckling vigor [73], it was not associated with adverse infant outcomes in a population-based cohort study [75].

When opioids are prescribed for severe postpartum pain, the clinician should review medication risks and benefits with the patient, including newborn signs of toxicity (eg, reduced muscle tone [limpness], not feeding well, not waking up to be fed). Use of all opioids should be limited to the lowest effective dose and prescribed for the shortest time required to control acute pain (table 3). Patients requiring any opioid should be switched to a nonopioid alternative as soon as the level of pain permits. Multimodal pain control with the use of regional anesthetic techniques, anesthetic blocks (such as transverse abdominis plane or quadratus lumborum), and scheduled dose acetaminophen and NSAIDs can reduce use of opioids and, in turn, risks associated with these drugs.

Preferred drug choices – Maternal use of oxycodone or hydrocodone does not appear to have the same risks as those reported for codeine and tramadol, which are described in the following bullet. Only two case reports have described infant opioid overdose thought to be attributable to transfer of oxycodone or hydrocodone through breastmilk and reversed by naloxone [76,77]. The Committee on Drugs of the American Academy of Pediatrics prefers use of butorphanol, morphine, or hydromorphone over other opioids [74]. However, based on the available data, the Society for Obstetric Anesthesia and Perinatology (SOAP) does not believe that a shift from oral oxycodone or hydrocodone to butorphanol, morphine, or hydromorphone is warranted [78]. Prolonged, frequent, and high-dose administration of any opioid may lead to neonatal sedation.

Levels of butorphanol and hydromorphone are very low in milk and thus are not likely to affect nursing infants. Morphine has limited transport into milk and poor oral bioavailability in infants. Morphine is preferable to meperidine or pethidine for postpartum analgesia during lactation [73]. The weight-adjusted relative infant dose of hydromorphone is 0.67 percent, so hydromorphone is unlikely to reach the infant in clinically significant levels. However, high doses of this drug should be used cautiously and the infant monitored for sedation since the drug is a strong opioid.

Agents warranting caution

-Codeine, tramadol – We suggest avoiding use of these drugs in breastfeeding individuals. The concern during breastfeeding is related to alterations in metabolism of the drugs due to genetic variations in cytochrome CYP2D6. This can result in high serum metabolite levels (ultra-rapid metabolizers) with potential transfer of these active metabolites into maternal milk causing excessive infant sedation and fatal overdoses in extreme cases [73,79-83]. The frequency of this variant varies based on ethnic background with an overall frequency in the United States population of 4 to 5 percent [84,85]. In 2017, the US Food and Drug Administration (FDA) issued warnings and contraindications for the use of codeine and tramadol for pain management in all children <12 years old and in breastfeeding individuals [83]. Similar warnings have been issued by other agencies, including Health Canada [86], European Medicines Agency [87], and ACOG [68]. If these drugs are used, use should be limited to a few days and the lowest effective dose, with close infant monitoring. The mother should stop use and call her provider if the infant appears to be unusually sleepy, has increased difficulty with breastfeeding or breathing, or appears to be weak.

Maternal risk guidelines state that central nervous system depression in the infant of an individual who breastfeeds while taking codeine appears to worsen after four days, likely due to accumulation of morphine from metabolism of codeine, so if possible, codeine should not be used for longer than four days [88]. If persistent pain necessitates its use, then an attempt should be made to decrease the dose or to switch to noncodeine analgesics.

-Meperidine – Meperidine should be avoided by nursing individuals because of consistent reports of dose-related neonatal sedation; its metabolites have a long half-life and may accumulate [89,90]. (See "Pain in children: Approach to pain assessment and overview of management principles", section on 'Agents not recommended'.)

-Aspirin – Aspirin should be used with caution in breastfeeding individuals because of the theoretical risk of Reye's syndrome. Reye's syndrome is associated with aspirin administration to infants with viral infections, but the risk from salicylate in breastmilk is unknown: There is a single case report of metabolic acidosis in an infant whose mother was taking a high dose of aspirin [91]. Daily low-dose aspirin is associated with low salicylate levels and does not appear to be excreted into breastmilk; thus, it is an option for use in breastfeeding individuals who require antiplatelet therapy [92]. The National Reye's Syndrome Foundation recommends against use of aspirin in breastfeeding individuals [93].

Safety of NSAIDs in individuals with hypertension — Although NSAIDs are known to cause elevations in blood pressure in nonpregnant hypertensive individuals, available evidence in hypertensive postpartum patients has not shown harmful effects. ACOG suggests considering NSAIDs as first-line agents for management of postpartum pain in all individuals, including those with hypertension [68]. Data on the effects of NSAIDs on blood pressure in postpartum individuals with hypertension is available separately. (See "Treatment of hypertension in pregnant and postpartum patients", section on 'Management'.)

DISCHARGE PLANNING — The American College of Obstetricians and Gynecologists (ACOG) recommends development of a postpartum care plan with pregnant individuals during the antepartum period. This plan is updated as needed and reviewed with the individual after giving birth. ACOG has also created a comprehensive list of the components of postpartum care [2]. Tables of the components are available online. In addition, the Alliance for Innovation on Maternal Health developed a maternal safety bundle of a set of strategies that health care professionals can use to improve the health and well-being of postpartum individuals (available online) [94].

Length of stay — Sparse, low- and moderate-quality evidence on the optimal length of stay after giving birth suggests a lack of adverse maternal or newborn effects from early discharge of healthy mothers and healthy term newborns [95]. Although atypical, discharge as early as one day after scheduled cesarean birth has been reported to be safe for mothers and newborns and satisfactory to mothers in some populations [96].

An expert panel of the World Health Organization agreed with most published guidelines that state a mother and healthy, term newborn of an uncomplicated birth should be observed by a skilled attendant for 24 to 48 hours after birth [97]. If the mother and newborn are discharged from the birth facility before 48 hours, then assessment by a qualified professional or skilled attendant within 24 to 48 hours after discharge is encouraged. Based on epidemiologic data, the first 24 to 48 hours are the most critical time for the mother and newborn; therefore, individualized skilled care during the immediate postnatal period can be lifesaving.

ACOG recommends that, in cases of postpartum discharge prior to 48 hours after a vaginal birth or 72 hours after a cesarean birth (excluding the day of birth), certain criteria should be met [98]. These include normal maternal vital signs, normal lochia, firm fundus, adequate urinary output, ability to tolerate diet, adequate pain control, ability to ambulate and care for themself and the newborn, no evidence of infection or impaired wound healing, and no abnormal physical or emotional findings. In addition, all laboratory results should have been addressed, including need for anti-D immune globulin if appropriate; instruction should be given for normal postpartum activities/exercise; and support resources for the new mother should be identified prior to discharge. Warning signs of serious maternal and infant postdelivery complications, including how to contact their health care provider, should be reviewed.

Patient education — Prior to the patient's discharge, they should be instructed on expected normal postpartum changes and care of themself (breasts, perineum, etc) and the newborn. (See "Overview of the routine management of the healthy newborn infant".)

Patients should also be instructed about signs of possible complications that should prompt them to seek further medical advice; these include, but are not limited to the following:

Excessive postpartum bleeding (eg, bleeding that saturates a peripad within an hour).

Any signs of sepsis, including fever; chills; rapid heart rate; lightheadedness or syncope; cold, clammy and pale or mottled skin; shortness of breath; cognitive changes (eg, confusion, disorientation, decreased alertness), slurred speech, low body temperature.

New or worsening perineal or uterine pain.

Dysuria.

Breast problems – (See "Common problems of breastfeeding and weaning".)

Dyspnea, chest pain, leg pain or swelling – (See "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity".)

Significant mood disturbance (eg, affecting relationships or normal activity) – (See "Postpartum unipolar major depression: Epidemiology, clinical features, assessment, and diagnosis" and "Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis" and "Posttraumatic stress disorder in adults: Treatment overview".)

Severe pain in any location (eg, head, chest, abdomen) is a cause for concern, as in any individual.

Use of dietary supplements — There is little scientific evidence on the value of routine postpartum use of dietary supplements, such as prenatal vitamins or multivitamins, iron, and micronutrients in individuals with a healthy diet and no specific nutritional deficiencies or anemia [99-104]. We advise most individuals to continue their prenatal vitamin and/or supplemental iron for six to eight weeks following birth, especially if they are breastfeeding. Iron is prescribed for individuals with anemia, and we discuss strategies to manage constipation, which may be caused by the iron supplementation. (See "Anemia in pregnancy", section on 'Postpartum'.)

Diet and supplements for breastfeeding individuals are reviewed separately. (See "Maternal nutrition during lactation".)

Activity — There are no data on which to base recommendations regarding postpartum physical activity. In particular, there are no high-quality data on which to base restrictions on lifting, climbing stairs, bathing, swimming, driving, or resuming vaginal intercourse, exercise, or work after giving birth [105].

After vaginal birth – A reasonable approach is to tell mothers to resume activities of daily living, including driving, exercise, and sexual intercourse, when they are comfortable performing these activities, and they should limit or avoid activities that cause pain or excessive fatigue. They should not engage in activities that require mental alertness (eg, driving or operating potentially dangerous equipment) until they have stopped using opioid analgesics.

If the individual is ready, they can probably resume vaginal intercourse safely as early as two weeks postpartum, as long as the perineum is healed and contraception is available. However, most individuals will not be ready to resume coitus this soon after giving birth because of fatigue, low sexual desire, pain, vaginal dryness or discharge (lochia), religious/cultural practices, psychological factors, or possibly postpartum blues or depression. Waiting at least six to eight weeks postpartum to resume sexual activity is common.

The abdominal wall regains most, if not all, of its normal muscular tone over several weeks. An abdominal exercise program can be started, if desired, any time after vaginal birth. Exercise may prevent abdominal muscle separation (rectus abdominis diastasis), but the extent to which exercise or other measures resolve or hasten resolution of diastasis has not been established. (See "Rectus abdominis diastasis", section on 'Spontaneous resolution'.)

After cesarean birth – Activity after cesarean birth is discussed separately. (See "Cesarean birth: Postoperative care, complications, and long-term sequelae", section on 'Early ambulation'.)

Contraception — Many individuals resume sexual relations by six weeks postpartum [106-108], which is a common time for a postpartum office visit. Therefore, contraceptive plans should be discussed in the third trimester and again before the individual leaves the hospital. Postpartum contraception counseling improves use and leads to fewer unplanned pregnancies [109].

In individuals not exclusively breastfeeding, ovulation can occur as early as 25 days after giving birth, so contraception should be initiated no later than the third postpartum week. In exclusively breastfeeding individuals, return of ovulation occurs later and is less predictable. During the first six months following birth, if an individual breastfeeds exclusively, uses no supplements, minimizes intervals without breastfeeding during the day and night, and remains amenorrheic, the risk of pregnancy is <5 percent in most populations [110]. Pregnancy rates rise among exclusively breastfeeding individuals after six months following birth, so contraception should be initiated.

Timing of initiation of contraceptive in the early postpartum period depends on the contraceptive method as some hormonal methods may affect lactation. For example, estrogen-progestin contraceptives should be avoided in breastfeeding individuals who are less than 30 days postpartum. (See "Contraception: Postpartum counseling and methods".)

Intrauterine contraception — Placement of intrauterine contraception within 10 minutes of placental delivery is an effective, long-term, but reversible alternative to sterilization. The device can be placed after vaginal or cesarean birth. The frequency of expulsion, however, is higher than with placement after the uterus has returned to its normal size. (See "Contraception: Postpartum counseling and methods", section on 'Intrauterine devices'.)

Permanent contraception — Permanent contraception (also called sterilization or tubal ligation) can be performed postpartum or as an interval procedure. Ideally, postpartum procedures are performed within 24 hours of birth but after the initial period of mother-infant breastfeeding and attachment. (See "Overview of female permanent contraception" and "Postpartum permanent contraception: Procedures".)

Follow-up visits — Postpartum care strategies (where, when, how, and by whom care is provided) that will improve maternal outcomes over the first year postpartum are important, but available evidence is often insufficient to determine best practices [111,112].

Timing and location — Available evidence does not allow clear conclusions regarding the optimum frequency, content, or sites (home versus office versus telephone contact) for postpartum follow-up [111,113,114]. An early postpartum visit at one to two weeks postpartum should be considered for individuals who have a cesarean birth, medical issues that require close follow-up, or risk factors for postpartum depression (eg, past episodes of depression, family history of mood disorder, concurrent stressful life events) or posttraumatic stress disorder (PTSD) after a traumatic birth experience. (See "Postpartum unipolar major depression: Epidemiology, clinical features, assessment, and diagnosis" and "Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis" and "Posttraumatic stress disorder in adults: Treatment overview".)

Traditionally, the postpartum visit had been recommended at four to six weeks after giving birth. In 2018, ACOG recommended an encounter (in person or by phone) with a maternal care provider within the first three weeks postpartum to address acute issues, with ongoing care as needed and a comprehensive postpartum visit no later than 12 weeks after birth [2]. The World Health Organization recommends routine postpartum evaluation at 3 days, 1 to 2 weeks, and 6 weeks [115]. Individuals with hypertensive diseases during pregnancy benefit from education regarding signs and symptoms of hypertensive complications, blood pressure monitoring, and early postpartum blood pressure follow-up within the first two weeks after discharge depending on severity of disease [116]. For patients with hypertensive disorders of pregnancy, ACOG suggests blood pressure evaluation within 72 hours of discharge in those with severe hypertension during pregnancy or postpartum and no later than 7 to 10 days postpartum in those with nonsevere hypertension [2].

The Pregnancy Risk Assessment Monitoring System reported 89 percent of United States postpartum individuals had a postpartum care visit, although the rate was significantly lower in some subgroups (71 percent for those with <8 years of education, 66 percent for those who had not received prenatal care) [117]. Counseling about the importance of the postpartum visit during prenatal care, scheduling the visit before hospital discharge, and providing reminders (mail, phone, text messaging) may be useful in improving attendance at this visit. Enabling virtual visits (telemedicine) and providing equipment, such as a blood pressure monitor, can also help with postpartum care engagement.

Patient assessment — The provider should assess the patient's adjustment to life with the newborn and update their history. Any problems that the patient perceives should be addressed. Routine topics that are readdressed at the follow-up visit include the health of the infant, the patient's mood, contraceptive plan (if not already in place), return to sexual activity, and any difficulties with breastfeeding.

Physical examination at the postpartum visit includes assessment of vital signs, thyroid, breasts (fissures, tenderness, lumps, skin changes), abdomen (diastasis, hernias), external genitalia/perineum (wound healing, fistulas), vagina (pelvic support), cervix, uterus/adnexa (size, tenderness, masses), and extremities.

Counseling — Complications that occurred during the pregnancy or postpartum should be reviewed in terms of the cause, risk of recurrence, and prevention, if possible (refer to individual topic reviews on pregnancy complications). Any underlying medical conditions that were present prior to or during the pregnancy should be addressed at the postpartum visit. Patients with placenta-mediated disorders such as fetal growth restriction, preeclampsia, abruption, and preterm birth and those with gestational diabetes need counseling and ongoing follow-up regarding their increased risks for developing cardiovascular disease and diabetes mellitus. Promoting healthy eating, exercise, maintaining/achieving a body mass index in the normal range, sleep health, and smoking cessation in smokers at this visit may reduce the risk of future cardiovascular disease. Care coordination is an important part of this process [118]. Timing of appropriate follow-up examinations should be reviewed. (See 'Screening' below.)

Plans for future pregnancy should be discussed. Both short (less than six months) and long (greater than 60 months) interpregnancy intervals are associated with increased risks of adverse outcome. The optimal interpregnancy interval is approximately 18 to 24 months. However, prolonging the interpregnancy interval may not be the best option for individuals over age 35 years or those with a strong family history of early menopause. (See "Interpregnancy interval: Optimizing time between pregnancies".)

Screening

Mental health conditions, including suicide, homicide, and substance use disorder, are leading causes of maternal mortality in the United States.

Depression, anxiety, and stress – We screen all individuals for postpartum depression and anxiety, as recommended by ACOG, the American Academy of Pediatrics, and the United States Preventive Service Task Force Recommendation Statement [119-123]. The validated questionnaire most commonly used for screening pregnant and postpartum individuals for depression is the Edinburgh Postnatal Depression Scale (figure 3A-B), but other validated tools such as the PHQ-9 can be used (table 4). The rationale for screening is that postpartum depression is common, the combination of screening and adequate support improves clinical outcomes, and treatment (particularly with cognitive behavioral therapy) is associated with symptom remission [119]. Direct and indirect evidence support a net benefit from screening and an absence of harm. Screening is appropriate whether or not the patient has a prior history of depression or depressive disorder. (See "Postpartum unipolar major depression: Epidemiology, clinical features, assessment, and diagnosis", section on 'Assessment'.)

The PHQ-4 screens for both anxiety and depression (table 5) and the GAD-7 scale (table 6) assesses severity of anxiety. Although there is no direct evidence on benefits of screening for anxiety disorders on health outcomes such as quality of life, functioning, or remission in screened versus unscreened pregnant and postpartum persons, psychological interventions to treat anxiety disorders are associated with a moderate benefit for reduced anxiety symptoms [123].

Screening for bipolar disorder (table 7) should be performed before initiating pharmacotherapy for depression because misdiagnosis can lead to inappropriate treatment, which may precipitate mania, mixed states, rapid cycling, or psychosis (which has been associated with self-harm and infanticide). (See "Bipolar disorder in postpartum women: Treatment".)

A symptom scale, such as the GAD seven-item (GAD-7) scale (calculator 1) can be helpful to try to quantify the severity of anxiety symptoms. (See "Generalized anxiety disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis" and "Comorbid anxiety and depression in adults: Epidemiology, clinical manifestations, and diagnosis".)

The possibility of postpartum posttraumatic stress disorder (PTSD) should also be considered, especially in patients in high-risk groups (eg, complicated pregnancy or delivery; negative emotional experience because of pain, fear, feeling disrespected, or other factors; history of sexual/physical trauma). A screening tool to identify patients at risk is available for primary care practices (table 8) and can be adapted for use in postpartum patients by asking questions such as: What was your birth experience like? Do you wish things had gone differently? Have you had upsetting thoughts in general since the birth? [124]. Providing advice and support, as well as referral when needed, can reduce the risk of PTSD developing. (See "Overview of the postpartum period: Disorders and complications", section on 'Mental health issues'.)

ACOG recommendations for obstetrical providers include the following principles [122,125]:

Be prepared to counsel patients on the benefits and risks of psychopharmacotherapy for perinatal mental health conditions when clinically indicated.

Initiate psychopharmacotherapy for perinatal depression or anxiety disorders, refer patients to appropriate behavioral health resources when indicated, or both.

Use a validated screening tool to monitor for response to treatment or remission of depression or anxiety symptoms. Titrate pharmacotherapy if clinically indicated, with the goal of remission of depressive and anxiety symptoms

Use Perinatal Psychiatry Access Programs as a resource for management and treatment guidance for individuals with mental health conditions.

If postpartum psychosis is suspected, immediate psychiatric hospitalization is generally indicated because psychosis has been associated with infanticide and suicide; continuous bedside observation can be used to keep the patient safe until transfer can occur.

Substance use – We recommend universal screening for postpartum use of nicotine, alcohol, illicit substances, and misuse of prescription drugs. We screen all individuals for drug misuse using a standardized screening tool (table 9), such as the NIDA quick screen (table 10), followed by a brief intervention in patients who screen positive, and then referral for treatment as indicated. (See "Brief intervention for unhealthy alcohol and other drug use: Goals and components" and "Brief intervention for unhealthy alcohol and other drug use: Efficacy, adverse effects, and administration" and "Opioid use disorder: Treatment overview".)

Intimate partner and domestic violence – We recommend screening all postpartum individuals for intimate partner violence and domestic violence. Ideally, screening should be performed at the initial prenatal visit, at least once per trimester, and again during postpartum care [126]. Screening should be routinely performed for individuals who have not accessed prenatal care or who have concerning signs or symptoms (table 11). Multiple validated screening tools are available. (See "Intimate partner violence: Diagnosis and screening".)

Human trafficking – We recommend screening for human trafficking in appropriate situations [127].

Diabetes – Individuals with gestational diabetes should undergo an oral glucose tolerance test postpartum. They should be counseled about the increased risk of future diabetes, even when the postpartum glucose tolerance test is normal. These individuals may benefit from lifestyle changes, such as weight loss if they have obesity. The traditional time to perform the glucose tolerance test is four to 12 weeks postpartum, which is inconvenient for new mothers, and thus they often fail to undergo testing. There is increasing evidence that performing the test on the second postpartum day when patients are still hospitalized provides reliable results and increases compliance to nearly 100 percent. If the patient is discharged before being tested, mail, telephone, and/or electronic reminders help to achieve compliance. (See "Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Follow-up'.)

Cardiovascular risk – Individuals with gestational diabetes, pregnancy-related hypertension, or preterm birth are at increased risk of future cardiovascular disease, even if postpartum blood pressures and glucose tolerance testing are normal. (See "Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Long-term risk' and "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Prognosis' and "Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Long-term maternal consequences'.)

ACOG recommends that clinicians make individuals with these complications of pregnancy aware of their increased risk for developing cardiovascular disease [2]. Including this information in their health record can facilitate ongoing monitoring and risk assessment. For individuals with preeclampsia, this may include yearly assessment of blood pressure, lipids, fasting blood glucose, and body mass index (see "Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"). Increased awareness about their cardiovascular risk may increase the individual's motivation to reduce modifiable risk factors, if present, by adopting a healthy lifestyle. (See "Overview of primary prevention of cardiovascular disease".)

Cervical cancer – Screening for cervical cancer should follow standard guidelines for cervical cancer screening, unless compliance with follow-up is an issue. (See "Screening for cervical cancer in resource-rich settings" and "Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing".)

Breast cancer – Screening mammography should be discussed with individuals aged 40 years and older. (See "Screening for breast cancer: Strategies and recommendations".)

Colon cancer – Colon cancer screening is commonly initiated at age 45 years in adults at average risk. (See "Screening for colorectal cancer: Strategies in patients at average risk".)

Breastfeeding issues — For the individual who is continuing to breastfeed at the postpartum visit, encouragement from the health care provider and discussion aimed at resolving breastfeeding challenges at this time has been correlated with improved breastfeeding continuation rates at four months postpartum [128]. Individuals planning to return to work outside of the home can be instructed on techniques for breast milk expression and storage while away from the infant [129]. Continued breastfeeding, even if not exclusive, still has health benefits for both the infant and nursing mother. (See "Breastfeeding: Parental education and support" and "Common problems of breastfeeding and weaning".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Postpartum infection" and "Society guideline links: Postpartum care" and "Society guideline links: Breastfeeding and infant nutrition".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topic (see "Patient education: Labor and childbirth (The Basics)")

Beyond the Basics topics (see "Patient education: Deciding to breastfeed (Beyond the Basics)" and "Patient education: Common breastfeeding problems (Beyond the Basics)" and "Patient education: Health and nutrition during breastfeeding (Beyond the Basics)" and "Patient education: Pumping breast milk (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

Definition, scope, and timing – The postpartum period (the "fourth trimester") begins upon birth of the newborn; the end is often considered the six to eight weeks after birth because the effects of pregnancy on many systems have largely returned to the prepregnancy state by this time. (See 'Definition of the postpartum period' above and 'Postpartum findings and changes' above.)

Routine inpatient postpartum care has several components, including rooming in, maternal monitoring, pain management, perineal care, and, in some cases, prophylaxis against thromboembolism and Rh alloimmunization. (See 'Routine maternal care' above.)

The American College of Obstetricians and Gynecologists (ACOG) recommends an encounter (in person or by phone) with a maternal care provider within the first three weeks postpartum to address acute issues, with ongoing care as needed and a comprehensive postpartum visit no later than 12 weeks after giving birth. For patients with hypertensive disorders of pregnancy, blood pressure should be evaluated daily for 72 hours postpartum and again no later than 7 to 10 days postpartum.

The World Health Organization (WHO) recommends routine postpartum evaluation at three days, one to two weeks, and six weeks. (See 'Follow-up visits' above.)

Pain management – Most patients do not require opioids for pain control after a vaginal birth. Multimodal strategies for postoperative pain control after cesarean birth should be employed to promote rapid recovery, allow the patient to care for their newborn, and minimize the need for postoperative opioids. (See 'Pain management' above.)

Analgesics that should be avoided or used with caution when breastfeeding include codeine, tramadol, meperidine, and aspirin. (See 'Safety of common analgesics in breastfeeding individuals' above.)

Laboratory testing – Postpartum inpatient laboratory testing should be based on specific indications, not routine. (See 'Laboratory testing' above.)

Breastfeeding – Human milk is the optimal food for all infants because of its proven health benefits to both infants and their mothers. Encouragement from the health care provider and discussion aimed at resolving breastfeeding challenges improves breastfeeding continuation rates. (See 'Support for breastfeeding and breast care' above and 'Breastfeeding issues' above.)

Immunization – Appropriate immunizations should be offered (figure 2 and table 1). (See 'Routine immunizations' above.)

Sexual relations and contraception – If the individual is ready, they can probably resume vaginal intercourse safely as early as two weeks postpartum, as long as the perineum is healed and contraception is available. However, most individuals will not be ready to resume coitus this soon after giving birth. Ovulation can occur as early as 25 days after delivery; therefore, the contraceptive desires of the couple should be addressed prior to hospital discharge and appropriate prescriptions given. (See 'Contraception' above and 'Activity' above.)

Depression screening – Screening for depression is routine. The validated questionnaire most commonly used is the Edinburgh Postnatal Depression Scale (figure 3A-B), but other validated tools can be used. Screening for bipolar disorder (table 7) should be performed before initiating pharmacotherapy for anxiety or depression because misdiagnosis can lead to inappropriate treatment, which may precipitate mania, mixed states, rapid cycling, or psychosis. (See 'Screening' above.)

  1. Dennis CL, Fung K, Grigoriadis S, et al. Traditional postpartum practices and rituals: a qualitative systematic review. Womens Health (Lond) 2007; 3:487.
  2. ACOG Committee Opinion No. 736: Optimizing Postpartum Care. Obstet Gynecol 2018; 131:e140. Reaffirmed 2021.
  3. Ravid D, Gidoni Y, Bruchim I, et al. Postpartum chills phenomenon: is it a feto-maternal transfusion reaction? Acta Obstet Gynecol Scand 2001; 80:149.
  4. Benson MD, Haney E, Dinsmoor M, Beaumont JL. Shaking rigors in parturients. J Reprod Med 2008; 53:685.
  5. Negishi H, Kishida T, Yamada H, et al. Changes in uterine size after vaginal delivery and cesarean section determined by vaginal sonography in the puerperium. Arch Gynecol Obstet 1999; 263:13.
  6. Montgomery E, Alexander J. Assessing postnatal uterine involution: a review and a challenge. Midwifery 1994; 10:73.
  7. Bergström S, Libombo A. Puerperal measurement of the symphysis-fundus distance. Gynecol Obstet Invest 1992; 34:76.
  8. Mulic-Lutvica A, Bekuretsion M, Bakos O, Axelsson O. Ultrasonic evaluation of the uterus and uterine cavity after normal, vaginal delivery. Ultrasound Obstet Gynecol 2001; 18:491.
  9. Mulic-Lutvica A, Axelsson O. Postpartum ultrasound in women with postpartum endometritis, after cesarean section and after manual evacuation of the placenta. Acta Obstet Gynecol Scand 2007; 86:210.
  10. Sokol ER, Casele H, Haney EI. Ultrasound examination of the postpartum uterus: what is normal? J Matern Fetal Neonatal Med 2004; 15:95.
  11. Wachsberg RH, Kurtz AB. Gas within the endometrial cavity at postpartum US: a normal finding after spontaneous vaginal delivery. Radiology 1992; 183:431.
  12. Buisson P, Tomikowski J, Santarelli J, Kapitaniak B. [Clinical and ultrasonographic study of uterine involution in postpartum physiology]. Rev Fr Gynecol Obstet 1993; 88:12.
  13. Shaamash AH, Ahmed AG, Abdel Latef MM, Abdullah SA. Routine postpartum ultrasonography in the prediction of puerperal uterine complications. Int J Gynaecol Obstet 2007; 98:93.
  14. SHARMAN A. Post-partum regeneration of the human endometrium. J Anat 1953; 87:1.
  15. Sherman D, Lurie S, Frenkel E, et al. Characteristics of normal lochia. Am J Perinatol 1999; 16:399.
  16. Oppenheimer LW, Sherriff EA, Goodman JD, et al. The duration of lochia. Br J Obstet Gynaecol 1986; 93:754.
  17. Chi C, Bapir M, Lee CA, Kadir RA. Puerperal loss (lochia) in women with or without inherited bleeding disorders. Am J Obstet Gynecol 2010; 203:56.e1.
  18. McLAREN HC. The involution of the cervix. Br Med J 1952; 1:347.
  19. Reyes FI, Winter JS, Faiman C. Postpartum disappearance of chorionic gonadotropin from the maternal and neonatal circulations. Am J Obstet Gynecol 1985; 153:486.
  20. Midgley AR Jr, Jaffe RB. Regulation of human gonadotropins. II. Disappearance of human chorionic gonadotropin following delivery. J Clin Endocrinol Metab 1968; 28:1712.
  21. Steier JA, Bergsjø PB, Myking OL. Disappearance of human chorionic gonadotropin after cesarean section with regard to fetal sex. Acta Obstet Gynecol Scand 2002; 81:403.
  22. Thurston RC, Luther JF, Wisniewski SR, et al. Prospective evaluation of nighttime hot flashes during pregnancy and postpartum. Fertil Steril 2013; 100:1667.
  23. Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol 2011; 117:657.
  24. The World Health Organization Multinational Study of Breast-feeding and Lactational Amenorrhea. II. Factors associated with the length of amenorrhea. World Health Organization Task Force on Methods for the Natural Regulation of Fertility. Fertil Steril 1998; 70:461.
  25. Rahman M, Mascie-Taylor CG, Rosetta L. The duration of lactational amenorrhoea in urban Bangladeshi women. J Biosoc Sci 2002; 34:75.
  26. Wasalathanthri S, Tennekoon KH. Lactational amenorrhea/anovulation and some of their determinants: a comparison of well-nourished and undernourished women. Fertil Steril 2001; 76:317.
  27. Li W, Qiu Y. Relation of supplementary feeding to resumptions of menstruation and ovulation in lactating postpartum women. Chin Med J (Engl) 2007; 120:868.
  28. Valeggia C, Ellison PT. Lactational amenorrhoea in well-nourished Toba women of Formosa, Argentina. J Biosoc Sci 2004; 36:573.
  29. Campbell OM, Gray RH. Characteristics and determinants of postpartum ovarian function in women in the United States. Am J Obstet Gynecol 1993; 169:55.
  30. Radwan H, Mussaiger AO, Hachem F. Breast-feeding and lactational amenorrhea in the United Arab Emirates. J Pediatr Nurs 2009; 24:62.
  31. Campino C, Ampuero S, Díaz S, Serón-Ferré M. Prolactin bioactivity and the duration of lactational amenorrhea. J Clin Endocrinol Metab 1994; 79:970.
  32. Stern JM, Konner M, Herman TN, Reichlin S. Nursing behaviour, prolactin and postpartum amenorrhoea during prolonged lactation in American and !Kung mothers. Clin Endocrinol (Oxf) 1986; 25:247.
  33. Gunderson EP, Abrams B, Selvin S. Does the pattern of postpartum weight change differ according to pregravid body size? Int J Obes Relat Metab Disord 2001; 25:853.
  34. Robson SC, Dunlop W, Moore M, Hunter S. Combined Doppler and echocardiographic measurement of cardiac output: theory and application in pregnancy. Br J Obstet Gynaecol 1987; 94:1014.
  35. Sibai BM. Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol 2012; 206:470.
  36. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122.
  37. Wu P, Green M, Myers JE. Hypertensive disorders of pregnancy. BMJ 2023; 381:e071653.
  38. Steele DW, Adam GP, Saldanha IJ, et al. Postpartum Home Blood Pressure Monitoring: A Systematic Review. Obstet Gynecol 2023; 142:285.
  39. VanderMeulen H, Petrucci J, Floros G, et al. The experience of postpartum bleeding in women with inherited bleeding disorders. Res Pract Thromb Haemost 2019; 3:733.
  40. Finlayson K, Crossland N, Bonet M, Downe S. What matters to women in the postnatal period: A meta-synthesis of qualitative studies. PLoS One 2020; 15:e0231415.
  41. Jaafar SH, Ho JJ, Lee KS. Rooming-in for new mother and infant versus separate care for increasing the duration of breastfeeding. Cochrane Database Syst Rev 2016; 2016:CD006641.
  42. Nicol B, Croughan-Minihane M, Kilpatrick SJ. Lack of value of routine postpartum hematocrit determination after vaginal delivery. Obstet Gynecol 1997; 90:514.
  43. Petersen LA, Lindner DS, Kleiber CM, et al. Factors that predict low hematocrit levels in the postpartum patient after vaginal delivery. Am J Obstet Gynecol 2002; 186:737.
  44. Ries LT, Kopelman JN, Macri CI. Evaluation of routine antepartum and postpartum blood counts. J Reprod Med 1998; 43:581.
  45. Steele HB, Goetzl L. The practical utility of routine postpartum hemoglobin assessment. Am J Obstet Gynecol 2014; 210:576.e1.
  46. Girault A, Deneux-Tharaux C, Sentilhes L, et al. Undiagnosed abnormal postpartum blood loss: Incidence and risk factors. PLoS One 2018; 13:e0190845.
  47. Partlow DB Jr, Chauhan SP, Justice L, et al. Diagnosis of postpartum infections: clinical criteria are better than laboratory parameter. J Miss State Med Assoc 2004; 45:67.
  48. Hartmann KE, Barrett KE, Reid VC, et al. Clinical usefulness of white blood cell count after cesarean delivery. Obstet Gynecol 2000; 96:295.
  49. Oladapo OT, Fawole B. Treatments for suppression of lactation. Cochrane Database Syst Rev 2012; :CD005937.
  50. Henkel S, Johnson SA, Reeves MF, et al. Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss A Randomized Controlled Trial. Obstet Gynecol 2023; 141:1115.
  51. Harris K, Murphy KE, Horn D, et al. Safety of Cabergoline for Postpartum Lactation Inhibition or Suppression: A Systematic Review. J Obstet Gynaecol Can 2020; 42:308.
  52. Yang Y, Boucoiran I, Tulloch KJ, Poliquin V. Is Cabergoline Safe and Effective for Postpartum Lactation Inhibition? A Systematic Review. Int J Womens Health 2020; 12:159.
  53. Jackson E, Curtis KM, Gaffield ME. Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 2011; 117:691.
  54. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697.
  55. Tepper NK, Boulet SL, Whiteman MK, et al. Postpartum venous thromboembolism: incidence and risk factors. Obstet Gynecol 2014; 123:987.
  56. Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top Guideline No. 37a, April 2015. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf (Accessed on November 01, 2017).
  57. Sigurdardottir T, Steingrimsdottir T, Geirsson RT, et al. Can postpartum pelvic floor muscle training reduce urinary and anal incontinence?: An assessor-blinded randomized controlled trial. Am J Obstet Gynecol 2020; 222:247.e1.
  58. Von Bargen E, Haviland MJ, Chang OH, et al. Evaluation of Postpartum Pelvic Floor Physical Therapy on Obstetrical Anal Sphincter Injury: A Randomized Controlled Trial. Female Pelvic Med Reconstr Surg 2021; 27:315.
  59. Booth JL, Sharpe EE, Houle TT, et al. Patterns of recovery from pain after cesarean delivery. Pain 2018; 159:2088.
  60. Komatsu R, Carvalho B, Flood PD. Recovery after Nulliparous Birth: A Detailed Analysis of Pain Analgesia and Recovery of Function. Anesthesiology 2017; 127:684.
  61. Fang X, Huan Y, Tao Y, et al. Incidence, severity, and determinants of uterine contraction pain after vaginal delivery: a prospective observational study. Int J Obstet Anesth 2021; 46:102961.
  62. Deussen AR, Ashwood P, Martis R, et al. Relief of pain due to uterine cramping/involution after birth. Cochrane Database Syst Rev 2020; 10:CD004908.
  63. Zhu Y, Huybrechts KF, Desai RJ, et al. Prescription opioid use after vaginal delivery and subsequent persistent opioid use and misuse. Am J Obstet Gynecol MFM 2020.
  64. Osmundson SS, Wiese AD, Min JY, et al. Delivery type, opioid prescribing, and the risk of persistent opioid use after delivery. Am J Obstet Gynecol 2019; 220:405.
  65. Peahl AF, Dalton VK, Montgomery JR, et al. Rates of New Persistent Opioid Use After Vaginal or Cesarean Birth Among US Women. JAMA Netw Open 2019; 2:e197863.
  66. Goodman SR, Drachenberg AM, Johnson SA, et al. Decreased postpartum use of oral pain medication after a single dose of epidural morphine. Reg Anesth Pain Med 2005; 30:134.
  67. Prabhu M, Garry EM, Hernandez-Diaz S, et al. Frequency of Opioid Dispensing After Vaginal Delivery. Obstet Gynecol 2018; 132:459.
  68. Pharmacologic Stepwise Multimodal Approach for Postpartum Pain Management: ACOG Clinical Consensus No. 1. Obstet Gynecol 2021; 138:507.
  69. Krohg A, Ullensvang K, Rosseland LA, et al. The Analgesic Effect of Ultrasound-Guided Quadratus Lumborum Block After Cesarean Delivery: A Randomized Clinical Trial. Anesth Analg 2018; 126:559.
  70. Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period. JAMA Intern Med 2016; 176:1286.
  71. Bateman BT, Franklin JM, Bykov K, et al. Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naïve women. Am J Obstet Gynecol 2016; 215:353.e1.
  72. Osmundson SS, Min JY, Grijalva CG. Opioid prescribing after childbirth: overprescribing and chronic use. Curr Opin Obstet Gynecol 2019; 31:83.
  73. Montgomery A, Hale TW, Academy Of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. Breastfeed Med 2012; 7:547.
  74. Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: An update on selected topics. Pediatrics 2013; 132:e796.
  75. Zipursky JS, Gomes T, Everett K, et al. Maternal opioid treatment after delivery and risk of adverse infant outcomes: population based cohort study. BMJ 2023; 380:e074005.
  76. Timm NL. Maternal use of oxycodone resulting in opioid intoxication in her breastfed neonate. J Pediatr 2013; 162:421.
  77. Meyer D, Tobias JD. Adverse effects following the inadvertent administration of opioids to infants and children. Clin Pediatr (Phila) 2005; 44:499.
  78. The Society for Obstetric Anesthesia and Perinatology Communication Comments in response to the ACOG/SMFM Practice Advisory on Codeine and Tramadol for Breastfeeding Women, June 10, 2017.
  79. Lam J, Kelly L, Ciszkowski C, et al. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. J Pediatr 2012; 160:33.
  80. Ciszkowski C, Madadi P, Phillips MS, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 2009; 361:827.
  81. Kelly LE, Rieder M, van den Anker J, et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics 2012; 129:e1343.
  82. Orliaguet G, Hamza J, Couloigner V, et al. A case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. Pediatrics 2015; 135:e753.
  83. US Food and Drug Administration Drug Safety Communications. FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM553814.pdf (Accessed on April 24, 2017).
  84. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91:321.
  85. Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7:257.
  86. Health Canada. New safety measures for prescription codeine and hydrocodone to further restrict use in children and adolescents. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59584a-eng.php?_ga=1.144008432.418636605.1493064052 (Accessed on August 01, 2016).
  87. European Medicines Agency. Codeine not to be used in children below 12 years for cough and cold. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/04/WC500186162.pdf (Accessed on April 27, 2015).
  88. Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009; 55:1077.
  89. Wittels B, Scott DT, Sinatra RS. Exogenous opioids in human breast milk and acute neonatal neurobehavior: a preliminary study. Anesthesiology 1990; 73:864.
  90. Wittels B, Glosten B, Faure EA, et al. Postcesarean analgesia with both epidural morphine and intravenous patient-controlled analgesia: neurobehavioral outcomes among nursing neonates. Anesth Analg 1997; 85:600.
  91. Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. Clin Pediatr (Phila) 1981; 20:53.
  92. U.S. National Library of Medicine. TOXNET. https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/f?./temp/~my0eg3:1 (Accessed on November 15, 2017).
  93. National Reye's Syndrome Foundation. Breastfeeding and Reye's syndrome. http://www.reyessyndrome.org/breastfeeding.html (Accessed on November 15, 2017).
  94. Stuebe AM, Kendig S, Suplee PD, D'Oria R. Consensus Bundle on Postpartum Care Basics: From Birth to the Comprehensive Postpartum Visit. Obstet Gynecol 2021; 137:33.
  95. Jones E, Stewart F, Taylor B, et al. Early postnatal discharge from hospital for healthy mothers and term infants. Cochrane Database Syst Rev 2021; 6:CD002958.
  96. Tan PC, Norazilah MJ, Omar SZ. Hospital discharge on the first compared with the second day after a planned cesarean delivery: a randomized controlled trial. Obstet Gynecol 2012; 120:1273.
  97. World Health Organization technical consultation on postpartum and postnatal care, 2010. whqlibdoc.who.int/hq/2010/WHO_MPS_10.03_eng.pdf (Accessed on February 15, 2012).
  98. American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Postpartum Care of the Mother. In: Guidelines for Perinatal Care, 8th edition, Sarah Kilpatrick, Lu-Ann Papile (Eds), 2017. p.284-285.
  99. Abe SK, Balogun OO, Ota E, et al. Supplementation with multiple micronutrients for breastfeeding women for improving outcomes for the mother and baby. Cochrane Database Syst Rev 2016; 2:CD010647.
  100. Sparling TM, Henschke N, Nesbitt RC, Gabrysch S. The role of diet and nutritional supplementation in perinatal depression: a systematic review. Matern Child Nutr 2017; 13.
  101. Miller BJ, Murray L, Beckmann MM, et al. Dietary supplements for preventing postnatal depression. Cochrane Database Syst Rev 2013; :CD009104.
  102. Naik P, Faridi MMA, Batra P, Madhu SV. Oral Supplementation of Parturient Mothers with Vitamin D and Its Effect on 25OHD Status of Exclusively Breastfed Infants at 6 Months of Age: A Double-Blind Randomized Placebo Controlled Trial. Breastfeed Med 2017; 12:621.
  103. Oliveira JM, Allert R, East CE. Vitamin A supplementation for postpartum women. Cochrane Database Syst Rev 2016; 3:CD005944.
  104. Markova V, Norgaard A, Jørgensen KJ, Langhoff-Roos J. Treatment for women with postpartum iron deficiency anaemia. Cochrane Database Syst Rev 2015; :CD010861.
  105. Minig L, Trimble EL, Sarsotti C, et al. Building the evidence base for postoperative and postpartum advice. Obstet Gynecol 2009; 114:892.
  106. McDonald EA, Brown SJ. Does method of birth make a difference to when women resume sex after childbirth? BJOG 2013; 120:823.
  107. McDonald EA, Gartland D, Woolhouse H, Brown SJ. Resumption of sex after a second birth: An Australian prospective cohort. Birth 2019; 46:173.
  108. Sok C, Sanders JN, Saltzman HM, Turok DK. Sexual Behavior, Satisfaction, and Contraceptive Use Among Postpartum Women. J Midwifery Womens Health 2016; 61:158.
  109. Lopez LM, Hiller JE, Grimes DA. Postpartum education for contraception: a systematic review. Obstet Gynecol Surv 2010; 65:325.
  110. Kennedy KI, Visness CM. Contraceptive efficacy of lactational amenorrhoea. Lancet 1992; 339:227.
  111. Saldanha IJ, Adam GP, Kanaan G, et al. Postpartum Care up to 1 Year After Pregnancy: A Systematic Review and Meta-Analysis. Comparative Effectiveness Review No. 261. AHRQ Publication No. 23-EHC010, Agency for Healthcare Research and Quality; Rockville, MD 2023.
  112. Saldanha IJ, Adam GP, Kanaan G, et al. Delivery Strategies for Postpartum Care: A Systematic Review and Meta-analysis. Obstet Gynecol 2023; 142:529.
  113. Lavender T, Richens Y, Milan SJ, et al. Telephone support for women during pregnancy and the first six weeks postpartum. Cochrane Database Syst Rev 2013; :CD009338.
  114. Yonemoto N, Nagai S, Mori R. Schedules for home visits in the early postpartum period. Cochrane Database Syst Rev 2021; 7:CD009326.
  115. WHO Guidelines on maternal, newborn, child and adolescent health http://www.who.int/maternal_child_adolescent/en/ (Accessed on April 24, 2018).
  116. Bernstein PS, Martin JN Jr, Barton JR, et al. National Partnership for Maternal Safety: Consensus Bundle on Severe Hypertension During Pregnancy and the Postpartum Period. Anesth Analg 2017; 125:540.
  117. Centers for Disease Control and Prevention (CDC). Postpartum care visits--11 states and New York City, 2004. MMWR Morb Mortal Wkly Rep 2007; 56:1312.
  118. Tully KP, Stuebe AM, Verbiest SB. The fourth trimester: a critical transition period with unmet maternal health needs. Am J Obstet Gynecol 2017; 217:37.
  119. Siu AL, US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, et al. Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 315:380.
  120. American Academy of Family Physicians clinical preventive service recommendation: Depression. 2016. http://www.aafp.org/patient-care/clinical-recommendations/all/depression.html (Accessed on January 03, 2018).
  121. Earls MF, Committee on Psychosocial Aspects of Child and Family Health American Academy of Pediatrics. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics 2010; 126:1032.
  122. Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4. Obstet Gynecol 2023; 141:1232.
  123. US Preventive Services Task Force, Barry MJ, Nicholson WK, et al. Screening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2023; 329:2163.
  124. Slade P, Murphy A, Hayden E. Identifying post-traumatic stress disorder after childbirth. BMJ 2022; 377:e067659.
  125. Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum. Obstet Gynecol 2023; 141:1262.
  126. ACOG Committee Opinion No. 518: Intimate partner violence. Obstet Gynecol 2012; 119:412. Reaffirmed 2022.
  127. ACOG Committee Opinion No. 787: Human Trafficking. Obstet Gynecol 2019; 134:e90.
  128. Mansbach IK, Palti H, Pevsner B, et al. Advice from the obstetrician and other sources: do they affect women's breast feeding practices? A study among different Jewish groups in Jerusalem. Soc Sci Med 1984; 19:157.
  129. Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #8: human milk storage information for home use for full-term infants (original protocol March 2004; revision #1 March 2010). Breastfeed Med 2010; 5:127.
Topic 6711 Version 133.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟